GALT - Galectin Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5218.94M
Enterprise Value 3173.22M
Trailing P/E N/A
Forward P/E 1-7.38
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)39.10
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6N/A

Trading Information

Stock Price History

Beta (3Y Monthly) 3.69
52-Week Change 3-30.60%
S&P500 52-Week Change 36.52%
52 Week High 36.9800
52 Week Low 33.1700
50-Day Moving Average 33.9297
200-Day Moving Average 34.4975

Share Statistics

Avg Vol (3 month) 3385.89k
Avg Vol (10 day) 3268.75k
Shares Outstanding 537.57M
Float 32.88M
% Held by Insiders 124.55%
% Held by Institutions 112.63%
Shares Short (Jun 28, 2019) 43.8M
Short Ratio (Jun 28, 2019) 48.62
Short % of Float (Jun 28, 2019) 49.34%
Short % of Shares Outstanding (Jun 28, 2019) 46.78%
Shares Short (prior month May 31, 2019) 44.06M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 26/1
Last Split Date 3Mar 23, 2012

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-115.50%
Return on Equity (ttm)-253.26%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)-19.6M
Diluted EPS (ttm)-0.4740
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)6.97M
Total Cash Per Share (mrq)0.15
Total Debt (mrq)115k
Total Debt/Equity (mrq)1.68
Current Ratio (mrq)8.25
Book Value Per Share (mrq)0.10

Cash Flow Statement

Operating Cash Flow (ttm)-9.95M
Levered Free Cash Flow (ttm)-5.09M